US 11,655,280 B2
Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods
Heiko Schuster, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Harpreet Singh, Tuebingen (DE); Gisela Schimmack, Tuebingen (DE); and Michael Roemer, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on May 6, 2022, as Appl. No. 17/738,453.
Application 17/738,453 is a continuation of application No. 17/472,290, filed on Sep. 10, 2021.
Application 17/472,290 is a continuation of application No. 16/526,114, filed on Jul. 30, 2019, abandoned.
Claims priority of provisional application 62/717,462, filed on Aug. 10, 2018.
Claims priority of provisional application 62/712,691, filed on Jul. 31, 2018.
Claims priority of application No. 102018118550.2 (DE), filed on Jul. 31, 2018; and application No. 102018119555.9 (DE), filed on Aug. 10, 2018.
Prior Publication US 2022/0267408 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 14/74 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); G01N 33/574 (2006.01); A61K 9/19 (2006.01); G16B 25/10 (2019.01); C12N 15/115 (2010.01)
CPC C07K 14/7051 (2013.01) [A61K 9/19 (2013.01); A61K 35/17 (2013.01); A61K 39/001111 (2018.08); A61P 35/00 (2018.01); C07K 14/70539 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C12N 5/0638 (2013.01); C12N 15/115 (2013.01); G01N 33/57492 (2013.01); G16B 25/10 (2019.02); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C12N 2310/16 (2013.01)] 20 Claims
 
1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of RPILKEQSSSSF (SEQ ID NO: 246), wherein said cancer is selected from the group consisting of gallbladder cancer, head and neck squamous cell carcinoma, squamous cell non-small cell lung cancer, and esophageal cancer.